Sudeep Pharma IPO: An Analysis
The Sudeep Pharma IPO, which closed on November 25, 2025, saw an extraordinary level of investor interest. The issue received a massive 93.72 times subscription, largely thanks to strong demand from large investors. This means far more people wanted shares than the company could offer. This level of demand suggests strong confidence in the company’s future.
Key Points
- Huge Demand: The IPO was subscribed 93.72 times.
- QIBs Lead: Qualified Institutional Buyers bid 213.08 times.
- NII Interest: Non-Institutional Investors bid 116.72 times.
- Retail Demand: Retail investors subscribed 15.65 times.
- Listing Date: Expected debut on November 28, 2025.
- Check Status: Use BSE, NSE, or MUFG Intime India links.
The company raised ₹895 crore through the IPO, aiming to use the money for expanding its production facility. Investors are now waiting to see if they’ve been allocated shares. The grey market trading – where shares trade before the official listing – shows the stock was valued at approximately ₹680, a 14.7% premium to the IPO price.
The IPO involved offering 1.6 million new shares and 13.5 million shares for sale. MUFG Intime India was the registrar for the issue, with ICICI Securities and IIFL Capital Services acting as lead managers. The company plans to invest the proceeds in new equipment and for general corporate purposes.
While the grey market provides an indication, remember that these figures are speculative. Actual listing performance could be different. It’s important to monitor the stock after it’s listed on the BSE and NSE.
Ultimately, the success of the Sudeep Pharma IPO reflects market confidence in the company’s potential growth.
